Form 4: Seres Therapeutics Director Acquires Stock Options

Seres Therapeutics Director Eric D. Shaff acquired stock options for 6,500 shares of common stock on July 8, 2026.

Summary

• Director Eric D. Shaff acquired 6,500 stock options for Seres Therapeutics, Inc. common stock.
• The transaction occurred on July 8, 2026.
• The stock options have an exercise price of $7.14 per share.
• These options are exercisable starting on July 7, 2036.
• The explanation for the vesting schedule indicates the options become exercisable on the earlier of July 8, 2027, or the day before the first annual stockholder meeting after July 8, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It represents a routine insider transaction (stock option grant) and does not provide new financial or operational information about the company.

Positives

• Director acquisition of stock options can signal confidence in the company's future prospects.
• The acquisition of 6,500 options provides potential upside for the director.

Negatives

• The filing is a routine Form 4 reporting a stock option grant, which does not inherently represent new positive or negative developments for the company's operations or financials.

Risks

• The value of the stock options is contingent on the future performance of Seres Therapeutics' stock price.
• The vesting schedule for the options is tied to specific future dates and events, introducing a time-based risk.

Future Outlook

The future outlook for Seres Therapeutics is not directly addressed in this Form 4 filing, which primarily reports on a stock option grant to a director. The value of these options will depend on the company's future performance and stock price.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The acquisition of stock options by a director is a common practice to align management's interests with shareholders, but it does not provide insight into the company's operational performance or strategic direction.

Related Party Transactions

• The acquisition of stock options by Director Eric D. Shaff is a form of compensation and represents a transaction between the company and a related party (director).

Stakeholder Impact

• Shareholders: The grant of options does not immediately dilute share count but represents potential future dilution if exercised. It can be seen as a positive alignment of director interests.
• Employees: This filing does not directly impact employees, but it is part of the overall compensation structure for key personnel.
• Management: The director benefits from potential future appreciation of the company's stock.

Next Steps

• The director may exercise the stock options if the stock price exceeds the exercise price and the options have vested.
• Future Form 4 filings will report any further transactions by the director.

Key Dates

Keywords

Form 4, Stock Options, Beneficial Ownership, Insider Trading, Seres Therapeutics, MCRB, Director, SEC Filing